MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment

Dow Jones06-22

By Connor Hart

Shares of MoonLake Immunotherapeutics rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks.

The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks.

The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments.

Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it said.

Moving forward, MoonLake said it plans to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab at the end of September, targeting to launch the treatment next year.

Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction which manifests as painful inflammatory skin lesions.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 22, 2026 07:14 ET (11:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645218540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645218540","market":"nz","top_or_hot":-1,"title":"MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks. \n</p>\n<p>\n  The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks. \n</p>\n<p>\n  The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments. \n</p>\n<p>\n  Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it said. \n</p>\n<p>\n  Moving forward, MoonLake said it plans to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab at the end of September, targeting to launch the treatment next year. \n</p>\n<p>\n  Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction which manifests as painful inflammatory skin lesions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 19:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks. \n</p>\n<p>\n  The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks. \n</p>\n<p>\n  The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments. \n</p>\n<p>\n  Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it said. \n</p>\n<p>\n  Moving forward, MoonLake said it plans to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab at the end of September, targeting to launch the treatment next year. \n</p>\n<p>\n  Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction which manifests as painful inflammatory skin lesions. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 07:14 ET (11:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645218540","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645218540","pubTimestamp":1782126840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of MoonLake Immunotherapeutics rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks.The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks.The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments.Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"MoonLake股价因化脓性汗腺炎治疗的后期数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of MoonLake Immunotherapeutics rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks. \n\n\n  The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks. \n\n\n  The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments. \n\n\n  Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it said. \n\n\n  Moving forward, MoonLake said it plans to submit a biologics license application to the U.S. Food and Drug Administration for sonelokimab at the end of September, targeting to launch the treatment next year. \n\n\n  Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction which manifests as painful inflammatory skin lesions. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:14 ET (11:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645218540","isCrawlerRequest":true}